Aptorum Group Limited (APM) Fair Value 2026

APM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.4 /10

32 fundamental signals · 10 models active

Value Trap Risk

(—/100)

Quick Summary — As of 2026-07-15, Aptorum Group Limited (APM) trades at $0.82, approximately 130% above CirclFi’s Bayesian DCF fair value of $0.36. QOC: 2.4/10. 10/13 models active.

Key Facts

Ticker
APM
Price
$0.82
Quality Score
2.4/10
Value Trap Risk
—/100
Models Active
10/13
Last Updated
Strength: CUCE Ensemble suggests +27.0% upside with 1% confidence
Risk: Below-average Quality Score of 2.4/10 signals weak fundamentals

Is Aptorum Group Limited (APM) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Aptorum Group Limited (APM) appears overvalued as of : the median of 10 independent fair value estimates is $0.58, 28.9% below the current price of $0.82. Estimates range from $0.01 to $3.72. APM scores 2.4/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Aptorum Group Limited Stock in 2026? →

Valuation Matrix

10 Intrinsic Value Models vs. Current Price ($0.82)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$0.36 -56.4%
Earnings Power Value
Low Conviction
$0.06 -92.5%
CUCE Ensemble
Low Conviction
$1.04 +27.0%
First Chicago
Low Conviction
$0.25 -69.8%

Unlock the Full Matrix

Access 6 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is Aptorum Group Limited (APM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Aptorum Group Limited's intrinsic value is estimated at a composite $0.98, showing conflicting signals at the current price of $0.82. While the average implied return is +20.0%, model disagreement is elevated with a gap of +454.0% between the most bullish and bearish estimates. The most optimistic model, ML-RIV, places fair value at $3.72 (+355.2%), while Regime Cross — the most conservative — estimates $0.01 (-98.8%). This +454.0% gap reflects genuine analytical uncertainty about Aptorum Group Limited's intrinsic worth.

What Do the Models Say About APM?

10 of 13 models are currently active for APM. Of these, 4 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates APM's intrinsic value at $0.36, implying -56.4% downside from the current price. See which stocks rank higher →

How Does APM Rank in Biotechnology?

Among 76 Biotechnology stocks, APM ranks #70 by Quality of Company score. CirclFi's QOC score of 2.4/10 evaluates 32 fundamental signals. A score of 2.4 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Aptorum Group Limited's positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including gene therapy and cell therapy innovation — shape both the opportunity set and risk profile.

Is APM a Value Trap?

The Value Trap algorithm is not active for APM. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Aptorum Group Limited. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Aptorum Group Limited scores 2.4 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +454.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every APM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across APM's 10 active models, average confidence is 12%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Aptorum Group Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

8 related Biotechnology stocks with 13-model coverage

Read investment analysis: ADMA · AUPH · ACAD · ALNY · ACRS

See all Biotechnology stocks ranked →

Frequently Asked Questions About Aptorum Group Limited

What is Aptorum Group Limited's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Aptorum Group Limited (APM) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.36. The Quality of Company score is 2.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is APM overvalued or undervalued right now?

At $0.82, 4 of 10 active models suggest APM may be undervalued, while 6 indicate potential overvaluation. The median of all 10 fair value estimates is $0.58, 28.9% below the current price of $0.82 — a consensus view that APM is overvalued. The assessment depends on which methodology best fits Aptorum Group Limited's business model in Biotechnology.

What does a Quality of Company score of 2.4 mean for APM?

Aptorum Group Limited's QOC of 2.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on APM?

CirclFi analyzes APM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Is APM a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for APM at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Aptorum Group Limited (APM) has a median fair value of $0.58 — 28.9% below the current price of $0.82 — as of 2026-07-15.” Source: circlfi.com/stock/APM/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on APM.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access